# US 8,278,485 B2 · Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,485 B2
- Document ID: US8278485B2
- Status: Granted
- Kind: B2
- Application number: 13/288,891
- Filed: 2011-11-03
- Published: 2012-06-21
- Granted: 2012-10-02
- Earliest claimed: 2006-06-19
- Assignees: Newron Pharmaceuticals S.p.A.
- Inventors: Elena Barbanti; Carla Caccia; Patricia Salvati; Francesco Velardi; Tiziano Ruffilli; Luigi Bogogna
- Web page: https://patentgrep.com/patent/US8278485B2

## CPC

- C07C 231/12: by reactions not involving the formation of carboxamide groups
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 231/18: by stereospecific synthesis
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to catalytic hydrogenation in the presence of a heterogeneous catalyst in a protic organic solvent.

## Claims

### Claim 1

High purity (S)-2-[4-(3-fluorobenzyloxy)benzylamino]propanamide (safinamide) or (S)-2-[4-(2-fluorobenzyloxy)benzylamino]propanamide (ralfinamide) of formula (Ia) or (Ib)
and pharmaceutically acceptable acid salts thereof, produced by the process of:
submitting a Schiff base intermediate respectively of formula (VIa) or (VIb)
to catalytic hydrogenation with hydrogen gas in the presence of a heterogeneous catalyst in a protic organic solvent and, when safinamide or ralfinamide are obtained in a free base form,
optionally converting said free base form to a salt thereof with a pharmaceutically acceptable acid.

### Claim 2 (depends on 1)

The product as in claim 1 wherein the catalytic hydrogenation is carried out by using an heterogeneous catalyst selected from nickel, rhodium, platinum and palladium catalysts on an inert support in the presence of a solvent selected from lower aliphatic (C1-C5) alkanols.

### Claim 3 (depends on 1)

The product as in claim 1 wherein the catalyst is a palladium or platinum catalyst.

### Claim 4 (depends on 1)

The product as in claim 1 wherein the catalyst is wet 5% Pt/C (50% H2O) or wet 10% Pd/C (50% H2O).

### Claim 5 (depends on 1)

The product as in claim 1 wherein the pharmaceutically acceptable acid is methanesulfonic acid.

### Claim 6 (depends on 1)

The product as in claim 1 wherein the hydrogen pressure is between 1 and 10 bars and the temperature is between 10° C. and 70° C.

### Claim 7 (depends on 6)

The product as in claim 6 wherein the hydrogen pressure is between 3 and 6 bars and the temperature is between 25° C. and 40° C.

### Claim 8 (depends on 1)

The product as in claim 1 wherein the catalytic hydrogenation is carried out on a Schiff base intermediate (VIa) or (VIb) which has been prepared through iminoalkylation of 4-(3-fluorobenzyloxy)benzaldehyde (IVa) or 4-(2-fluorobenzyloxy)benzaldehyde (IVb)
with L-alaninamide in the presence of a protic organic solvent.

### Claim 9 (depends on 8)

The product as in claim 8 wherein the L-alaninamide is employed as an acid addition salt thereof in the presence of a base in an amount sufficient to set free L-alaninamide from its salt.

### Claim 10 (depends on 8)

The product as in claim 8 where the catalytic hydrogenation of the Schiff base intermediate is performed on the same reaction mixture resulting from the completion of the iminoalkylation reaction under conditions which provoke the precipitation of said Schiff base intermediate to obtain a suspension of said intermediate in the same reaction solvent.

### Claim 11 (depends on 8)

The product as in claim 8 wherein the Schiff base intermediate resulting from the completion of the iminoalkylation reaction is isolated before undergoing the catalytic hydrogenation step.

### Claim 12 (depends on 8)

The product as in claim 8 wherein the 4-(3-fluorobenzyloxy)benzaldehyde or 4-(2-fluorobenzyloxy)benzaldehyde of formula (IVa) or (IVb) employed as the starting material to obtain the Schiff base intermediate of formula (VIa) or (VIb) contains less than 0.03% (by weight), of the respective impurities 3-(3-fluorobenzyl)-4-(3-fluorobenzyloxy)benzaldehyde (Va) or 3-(2-fluorobenzyl)-4-(2-fluorobenzyloxy)benzaldehyde (Vb)

### Claim 13 (depends on 12)

The product according to claim 12 wherein the 4-(3-fluorobenzyloxy)benzaldehyde (IVa) or 4-(2-fluorobezyloxy)benzaldehyde (IVb) is obtained by alkylation of 4-hydroxybenzaldehyde with, respectively, a 3-fluorobenzyl or 2-fluorobenzyl derivative (IIIa) or (IIIb)
where Y is a leaving group selected from Cl, Br, I, OSO2CH3 and OSO2—C6H4-pCH3, in the presence of a base, and is submitted to crystallization before the use in the successive reaction step.

### Claim 14 (depends on 13)

The product as in claim 13 wherein Y is Cl.

### Claim 15 (depends on 13, 14)

The product as in claim 13 or 14 wherein the crystallization is carried out by adding an inert organic non-solvent to a solution of the 4-(3-fluorobenzyloxy)benzaldehyde (IVa) or 4-(2-fluorobenzyloxy)benzaldehyde (IVb) in an inert organic solvent.

### Claim 16 (depends on 15)

The product as in claim 15 wherein the inert organic non-solvent is selected from lower aliphatic hydrocarbons and the inert organic solvent is selected from aromatic hydrocarbons.

### Claim 17 (depends on 16)

The product as in claim 16 wherein the lower aliphatic hydrocarbon is n-hexane and the aromatic hydrocarbon is toluene.

### Claim 18 (depends on 13, 14)

The product as in any of claims 13 and 14 wherein the crystallization is carried out by dissolving the 4-(3-fluorobenzyloxy)benzaldehyde (IVa) or 4-(2-fluorobenzyloxy)benzaldehyde (IVb) in a hot solvent selected from cyclohexane, and a di(C3-C4)alkyl ether at reflux, and then cooling the solution to a temperature at or below room temperature.

### Claim 19 (depends on 13, 14)

The product as in any of claims 13 and 14 wherein the alkylation reaction is carried out under phase transfer conditions.

### Claim 20 (depends on 19)

The product as in claim 19 wherein the alkylation under phase transfer condition is performed in a solid/liquid system wherein the reagents and the phase transfer catalyst are dissolved in a liquid organic phase and the solid phase is constituted by an inorganic base or a salt of 4-hydroxy benzaldehyde with said inorganic base.

### Claim 21 (depends on 19)

The product as in claim 19 wherein the alkylation under phase transfer conditions is performed in a liquid/liquid system wherein the alkylating reagent 3-fluorobenzyl or 2-fluorobenzyl derivative of formula (IIIa) or (IIIb) is dissolved in a liquid organic phase and the 4-hydroxybenzaldehyde is dissolved in an aqueous phase as a salt with an inorganic base.

### Claim 22 (depends on 19)

The product as in claim 19 wherein the phase transfer catalyst is selected from quaternary ammonium or phosphonium salts or polyethyleneglycols of low molecular weight.

### Claim 23 (depends on 22)

The product of claim 22 wherein the amount of phase transfer catalyst employed is between 0.02 to 1 mole per mole of 4-hydroxybenzaldheyde.

### Claim 24 (depends on 23)

The product as in claim 23 wherein the amount of phase-transfer catalyst is 0.1 to 1 mole per mole of 4-hydroxybenzaldehyde.

### Claim 25 (depends on 20)

The product as in claim 20 wherein the organic solvent of the liquid organic phase is selected from dialkyl ethers and aromatic hydrocarbons.

### Claim 26 (depends on 21)

The product as in claim 21 wherein the molar ratio between the alkylating reagent of formula (IIIa) or (IIIb), and 4-hydroxybenzaldehyde is between 0.6 and 1.5.

### Claim 27 (depends on 20)

The product as in claim 20 wherein the temperature is between 60° C. and 160° C.

### Claim 28 (depends on 20)

The product as in claim 20 wherein the inorganic base is selected from Na2CO3, K2CO3, NaOH and KOH, the temperature is between 80° C. and 120° C., and the ratio between the alkylating reagent of formula (IIIa) or (IIIb), and 4-hydroxybenzaldehyde is between 0.9 and 1.1.

### Claim 29 (depends on 12)

The product as in claim 12 wherein safinamide or ralfinamide or their pharmaceutically acceptable acid salts, have a content of the respective impurity (S)-2-[3-(3-fluorobenzyl)-4-(3-fluorobenzyloxy)-benzylamino]propanamide (IIa) or (S)-2-[3-(2-fluorobenzyl)-4-(2-fluorobenzyloxy)-benzylamino]propanamide (IIIb)
or their pharmaceutically acceptable acid salts, which is lower than 0.03% (by weight).

### Claim 30 (depends on 29)

The product as in claim 29 wherein the pharmaceutically acceptable acid is methanesulfonic acid and the content of the respective impurity of formula (IIa) or (IIb) as the salt with methanesulfonic acid is lower than 0.01% (by weight).

### Claim 31 (depends on 3)

The product as in claim 3 wherein the catalyst is platinum.

### Claim 32 (depends on 4)

The product as in claim 4 wherein the catalyst is wet 5% Pt/C (50% H2O).

### Claim 33 (depends on 12)

The product as in claim 12 wherein the 4-(3-fluorobenzyloxy)benzaldehyde or 4-(2-fluorobenzyloxy)benzaldehyde of formula (IVa) or (IVb) employed as the starting material to obtain the Schiff base intermediate of formula (VIa) or (VIb) contains less than 0.01% (by weight), of the respective impurities 3-(3-fluorobenzyl)-4-(3-fluorobenzyloxy)benzaldehyde (Va) or 3-(2-fluorobenzyl)-4-(2-fluorobenzyloxy)benzaldehyde (Vb).

### Claim 34 (depends on 18)

The product as in claim 18 wherein the hot solvent is diisopropylether.

### Claim 35 (depends on 18)

The product as in claim 18 wherein the temperature is about 10-15° C.

### Claim 36

A method for treating epilepsy comprising administering to a patient in need thereof an effective amount of high purity safinamide or a pharmaceutically acceptable acid salt thereof wherein the content of the impurity (S)-2-[3-(3-fluorobenzyl)-4-(3-fluorobenzyloxy)-benzylamino]propanamide of formula (IIa)
or a pharmaceutically acceptable acid salt thereof is lower than 0.03% (by weight).

### Claim 37

A method for treating Parkinson's disease comprising administering to a patient in need thereof an effective amount of high purity safinamide or a pharmaceutically acceptable acid salt thereof wherein the content of the impurity (S)-2-[3-(3-fluorobenzyl)-4-(3-fluorobenzyloxy)-benzylamino]propanamide of formula (IIa)
or a pharmaceutically acceptable acid salt thereof is lower than 0.03% (by weight).

### Claim 38

A method for treating Alzheimer's disease comprising administering to a patient in need thereof an effective amount of high purity safinamide or a pharmaceutically acceptable acid salt thereof wherein the content of the impurity (S)-2-[3-(3-fluorobenzyl)-4-(3-fluorobenzyloxy)-benzylamino]propanamide of formula (IIa)
or a pharmaceutically acceptable acid salt thereof is lower than 0.03% (by weight).

### Claim 39

A method for treating depression comprising administering to a patient in need thereof an effective amount of high purity safinamide or a pharmaceutically acceptable acid salt thereof wherein the content of the impurity (S)-2-[3-(3-fluorobenzyl)-4-(3-fluorobenzyloxy)-benzylamino]propanamide of formula (IIa)
or a pharmaceutically acceptable acid salt thereof is lower than 0.03% (by weight).

### Claim 40

A method for treating restless legs syndrome comprising administering to a patient in need thereof an effective amount of high purity safinamide or a pharmaceutically acceptable acid salt thereof wherein the content of the impurity (S)-2-[3-(3-fluorobenzyl)-4-(3-fluorobenzyloxy)-benzylamino]propanamide of formula (IIa)
or a pharmaceutically acceptable acid salt thereof is lower than 0.03% (by weight).

### Claim 41

A method for treating migraine comprising administering to a patient in need thereof an effective amount of high purity safinamide or a pharmaceutically acceptable acid salt thereof wherein the content of the impurity (S)-2-[3-(3-fluorobenzyl)-4-(3-fluorobenzyloxy)-benzylamino]propanamide of formula (IIa)
or a pharmaceutically acceptable acid salt thereof is lower than 0.03% (by weight).

### Claim 42

A method for treating pain conditions comprising administering to a patient in need thereof an effective amount of high purity ralfinamide or a salt thereof with a pharmaceutically acceptable acid wherein the content of the impurity (S)-2-[3-(2-fluorobenzyl)-4-(2-fluorobenzyloxy)-benzylamino]propanamide of formula (IIb)
or a pharmaceutically acceptable acid salt thereof is lower than 0.03% (by weight).

### Claim 43

A method for treating migraine comprising administering to a patient in need thereof an effective amount of high purity ralfinamide or a salt thereof with a pharmaceutically acceptable acid wherein the content of the impurity (S)-2-[3-(2-fluorobenzyl)-4-(2-fluorobenzyloxy)-benzylamino]propanamide of formula (IIb)
or a pharmaceutically acceptable acid salt thereof is lower than 0.03% (by weight).

### Claim 44

A method for treating bipolar disorders comprising administering to a patient in need thereof an effective amount of high purity ralfinamide or a salt thereof with a pharmaceutically acceptable acid wherein the content of the impurity (S)-2-[3-(2-fluorobenzyl)-4-(2-fluorobenzyloxy)-benzylamino]propanamide of formula (IIb)
or a pharmaceutically acceptable acid salt thereof is lower than 0.03% (by weight).

### Claim 45

A method for treating depressions comprising administering to a patient in need thereof an effective amount of high purity ralfinamide or a salt thereof with a pharmaceutically acceptable acid wherein the content of the impurity (S)-2-[3-(2-fluorobenzyl)-4-(2-fluorobenzyloxy)-benzylamino]propanamide of formula (IIb)
or a pharmaceutically acceptable acid salt thereof is lower than 0.03% (by weight).

### Claim 46

A method for treating cardiovascular disorders comprising administering to a patient in need thereof an effective amount of high purity ralfinamide or a salt thereof with a pharmaceutically acceptable acid wherein the content of the impurity (S)-2-[3-(2-fluorobenzyl)-4-(2-fluorobenzyloxy)-benzylamino]propanamide of formula (IIb)
or a pharmaceutically acceptable acid salt thereof is lower than 0.03% (by weight).

### Claim 47

A method for treating inflammatory disorders comprising administering to a patient in need thereof an effective amount of high purity ralfinamide or a salt thereof with a pharmaceutically acceptable acid wherein the content of the impurity (S)-2-[3-(2-fluorobenzyl)-4-(2-fluorobenzyloxy)-benzylamino]propanamide of formula (IIb)
or a pharmaceutically acceptable acid salt thereof is lower than 0.03% (by weight).

### Claim 48

A method for treating urogenital disorders comprising administering to a patient in need thereof an effective amount of high purity ralfinamide or a salt thereof with a pharmaceutically acceptable acid wherein the content of the impurity (S)-2-[3-(2-fluorobenzyl)-4-(2-fluorobenzyloxy)-benzylamino]propanamide of formula (IIb)
or a pharmaceutically acceptable acid salt thereof is lower than 0.03% (by weight).

### Claim 49

A method for treating metabolic disorders comprising administering to a patient in need thereof an effective amount of high purity ralfinamide or a salt thereof with a pharmaceutically acceptable acid wherein the content of the impurity (S)-2-[3-(2-fluorobenzyl)-4-(2-fluorobenzyloxy)-benzylamino]propanamide of formula (IIb)
or a pharmaceutically acceptable acid salt thereof is lower than 0.03% (by weight).

### Claim 50

A method for treating gastrointestinal disorders comprising administering to a patient in need thereof an effective amount of high purity ralfinamide or a salt thereof with a pharmaceutically acceptable acid wherein the content of the impurity (S)-2-[3-(2-fluorobenzyl)-4-(2-fluorobenzyloxy)-benzylamino]propanamide of formula (IIb)
or a pharmaceutically acceptable acid salt thereof is lower than 0.03% (by weight).
